SCHEMBL2024082

SCHEMBL2024082

CN1CCN(c2ccc(-c3cc(Cl)c4c(c3)CN(CC3CC3)C4=O)cn2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS O95271 3/20 0.43
ALK Q9UM73 6/20 0.41
PIK3CG P48736 1/20 0.41
GRM2 Q14416 1/20 0.40
RET P07949 4/20 0.39
MET P08581 4/20 0.39
FLT3 P36888 3/20 0.39
AURKB Q96GD4 3/20 0.39
MELK Q14680 3/20 0.39
SRC P12931 2/20 0.39
AURKA O14965 2/20 0.39
PDGFRA P16234 2/20 0.39
KDR P35968 2/20 0.39
KIT P10721 1/20 0.39
AXL P30530 1/20 0.39
TYRO3 Q06418 1/20 0.39
DDR1 Q08345 1/20 0.39
MERTK Q12866 1/20 0.39
CNR2 P34972 1/20 0.39
JAK2 O60674 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2026458 0.89 TNKS (0.43) TNKSALKPIK3CGRETMET
SCHEMBL2026378 0.84 ALK (0.44) TNKSALKPIK3CGGRM2RET
SCHEMBL8271898 0.79 TNKS (0.38) TNKSALKPIK3CGGRM2RET
SCHEMBL2023776 0.77 CYP11B2 (0.46) PIK3CGGRM2
SCHEMBL2024043 0.74 TNKS (0.41) TNKSALKPIK3CGGRM2RET
SCHEMBL12581493 0.74 PARP1 (0.48) TNKSTNK2
SCHEMBL2023194 0.71 PARP1 (0.40) PIK3CGGRM2
SCHEMBL2024499 0.71 PARP1 (0.39) MAPK1
SCHEMBL2023271 0.70 GRM2 (0.54) TNKSALKPIK3CGGRM2RET
SCHEMBL1003707 0.68 PARP1 (0.38) PIK3CGGRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2357169-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators AstraZeneca AB (SE) 2011-08-17 EP disclosed
EP-2357169-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators AstraZeneca AB (SE) 2011-08-17 EP disclosed
US-7968570-B2 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2011-06-28 US disclosed
US-7968570-B2 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2011-06-28 US disclosed
US-7968570-B2 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2011-06-28 US disclosed
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 US disclosed
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 US disclosed
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators GRM1, GRIN1, GRM3 TNKS 3673/4885ALK 3801/4885PIK3CG 1735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.